Evidence map›Paper›PMID 37064148›Full record

ArticleFrontiers in oncology2023

Development and validation of a nomogram model for lung cancer based on radiomics artificial intelligence score and clinical blood test data.

Wenteng Hu, Xu Zhang, Ali Saber, Qianqian Cai, Min Wei, Mingyuan Wang, Zijian Da, Biao Han, Wenbo Meng, Xun Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Wenteng HuThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Xu ZhangThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Ali SaberSaber Medical Genetics Laboratory, Almas Medical Complex, Rasht, Iran.
Qianqian CaiThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Min WeiThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Mingyuan WangThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Zijian DaThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Biao HanThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Wenbo MengThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Xun LiThe First Clinical Medical School of Lanzhou University, Lanzhou, Gansu, China.
Lanzhou University · CNFirst Hospital of Lanzhou University · CNGuilan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Artificial intelligence Methods: Between 2018 and 2021, 584 individuals (358 patients with lung cancer and 226 individuals with lung nodules other than cancer as control) were enrolled prospectively. Machine learning algorithms including lasso regression and random forest (RF) were used to select variables from blood test data, Logistic regression analysis was used to reconfirm the features to build the nomogram model. The predictive performance was assessed by performing the receiver operating characteristic (ROC) curve analysis as well as calibration, clinical decision and impact curves. A cohort of 48 patients was used to independently validate the model. The subgroup application was analyzed by pathological diagnosis. Findings: A total of 584 patients were enrolled (358 lung cancers, 61.30%,226 patients for the control group) to establish the model. The integrated model identified eight potential factors including carcinoembryonic antigen (CEA), AI score, Pro-Gastrin Releasing Peptide (ProGRP), cytokeratin 19 fragment antigen21-1(CYFRA211), squamous cell carcinoma antigen(SCC), indirect bilirubin(IBIL), activated partial thromboplastin time(APTT) and age. The area under the curve (AUC) of the nomogram was 0.907 (95% CI, 0.881-0.929). The decision and clinical impact curves showed good predictive accuracy of the model. An AUC of 0.844 (95% CI, 0.710 - 0.932) was obtained for the external validation group. Conclusion: The nomogram model integrating AI and clinical data can accurately predict lung cancer, especially for the squamous cell carcinoma subtype.

Indexed as

artificial intelligencelung cancermachine learning (ML)prediction modelpulmonary nodule

Identifiers

PMID37064148
PMCPMC10090418
OpenAlexW4361201332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.